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Figure 1. Apoptosis Pathway2

• Cutaneous melanoma is the most
aggressive form of skin cancer
• Immunotherapies and single-agent
targeted therapies have high relapse
rates
• 70% of cutaneous melanoma patients
have increased expression of BCL2
family proteins (e.g. BCL2 and MCL1)
that prevent apoptosis1
• Although BCLXL and BCLXS are
respectively described as anti-apoptotic
and pro-apoptotic proteins in other
cancers, their roles are not well
understood in melanoma
• BCL2 is a marker of chemotherapy treatment resistance and a marker of
response to BCL2 inhibitors such as Venetoclax and Navitoclax - however, the
role of BCLXL in treatment response is not known, especially in melanoma
• Shorter and potentially antagonistic isoform, BCLXS, has not been studied in
melanoma
• Navitoclax targets BCL2 and BCLXL, while Venetoclax solely targets BCL2
• Navitoclax’s action on BCLXS is unknown

Conclusions
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Figure 2. BCLXL-upregulated cells demonstrated less sub-G1 phase than parental when treated with 10 uM of Navitoclax. BCLXS-upregulated cells demonstrated even less
sub-G1 phase than BCLXL-upregulated cells when treated with 10 uM of Navitoclax. The same patterns are seen with Venetoclax, with 10 uM causing less sub-G1 phase for
BCLXL-upregulated cells and even less sub-G1 phase for BCLXS-upregulated cells. A G2/M spike was seen in BCLXL cells treated with 1 uM Navitoclax, however no similar
spike was seen in any other sample or trial.

Cell Viability after Single-Agent Treatment

5-Day Cell Growth
Figure 3. Parental
4257 cells were the
most sensitive to
Navitoclax.
Interestingly
BCLXS-upregulated
cells were the least
sensitive to
Navitoclax, followed
by BCLXLupregulated cells.
Venetoclax
treatment did not
induce significant
differences in cellline growth rates.

Hypotheses
• BCLXL-upregulated cells will demonstrate a greater rate of growth than parental.
BCLXS-upregulated cells will have the inverse effect, based on prior evidence in
other cancers
• Navitoclax will induce greater cell death in BCLXL-upregulated cells, but not in
BCLXS-upregulated cells
• BCLXL and BCLXS will have opposite effects on mitochondrial energetics, based on
prior evidence of their opposite tumorigenetical effects on other cancers
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Cell Cycle Analysis: Cells were seeded in 6-well plates overnight, then treated
20 with
the indicated doses of Navitoclax or Venetoclax. After 72 hours, cells were harvested,
stained with propidium iodide, and cell cycle analysis was performed3
10 and
Cell Viability: Cells were seeded in 96 well plates then treated with Navitoclax
Venetoclax. Cell viability was evaluated after 72 hours (3 days)
Cell Growth: Cells were seeded in 96 well plates then cell growth was evaluated over
0
a period of 5 days
0 test 20
Cell Energetics: Cells were seeded in Seahorse XF assay plates and mito stress
was performed following the manufacturer’s instructions
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BCLXL upregulation had a negative
effect on cell growth as well as drug
sensitivity relative to parental cells,
going against its previously
documented tumorigenic role in
other cancers
BCLXS upregulation had a positive
effect on cell growth and a negative
effect on drug sensitivity relative to
parental cells going against its
previously documented tumor
suppressive role in other cancers
BCLXS-upregulated cells had lower
drug sensitivity than BCLXLupregulated cells
BCLXL upregulation caused a
decrease in apoptosis following
BCL2 inhibitor drug treatment, and
BCLXS upregulation caused an
even greater decrease
BCLXL upregulation caused a
decrease in cell respiration and
glycolysis
BCXLS upregulation also caused a
decrease in cell respiration and
glycolysis
Considering the data, BCLXL and
BCLXS likely play differential roles in
cutaneous melanoma as compared
to other cancers
Results may be partially due to
WM4257’s low levels of BCL2
expression levels – research is
needed on high-BCLX expression
cell lines
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Figure 4.
BCLXSupregulated cells
•
possessed
greater rates of
growth than
•
parental and
BCLXLupregulated cells,
going against the
currently known •
role of BCL-XS as
described in
literature as a
tumor
suppressor.
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• One BCLXL-upregulated cell line clone and one BCLXS-upregulated cell line clone
were engineered from the low-BCL2-expressing melanoma cell line WM4257 via
lentiviral constructs
• Clones were made to be puromycin resistant.
40

•

Cell cycle analysis of parental and BCLXL or BCLXS over-expressing cells
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